$1.06
-0.01 (-0.93%)
Open$1.07
Previous Close$1.07
Day High$1.12
Day Low$1.00
52W High$4.96
52W Low$1.06
Volume—
Avg Volume18.2K
Market Cap13.95M
P/E Ratio—
EPS$-2.89
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,907.5% upside
Current
$1.06
$1.06
Target
$42.48
$42.48
$23.35
$42.48 avg
$52.53
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 803.4K | 1.18M | 4.21M |
| Net Income | -46,029,650 | -17,884,542 | -76,163 |
| Profit Margin | -6,407.4% | -1,605.8% | -1.8% |
| EBITDA | -44,555,905 | -17,808,595 | -73,642 |
| Free Cash Flow | — | — | -41,548 |
| Rev Growth | +131.9% | +78.7% | +17.4% |
| Debt/Equity | 250.29 | 250.29 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.55 | +0.40% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $409.22 | +4.08% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $519.07 | +1.63% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $811.01 | +1.61% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $253.98 | +3.95% | 40.0 | 32.33B |